相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)
Morton Coleman et al.
LEUKEMIA & LYMPHOMA (2021)
On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors
Franck Morschhauser et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study
Martin Dreyling et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma
Georg Lenz et al.
LEUKEMIA (2020)
Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial.
Martin Hutchings et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).
Caron A. Jacobson et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Tumor infiltrating T cells influence prognosis in stage I-III non-small cell lung cancer
Arik Bernard Schulze et al.
JOURNAL OF THORACIC DISEASE (2020)
Copanlisib in the treatment of non-Hodgkin lymphoma
Mayur Narkhede et al.
FUTURE ONCOLOGY (2020)
Insulin-Driven PI3K-AKT Signaling in the Hepatocyte Is Mediated by Redundant PI3Kα and PI3Kβ Activities and Is Promoted by RAS
Angela Molinaro et al.
CELL METABOLISM (2019)
High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy
Alexandre V. Hirayama et al.
BLOOD (2019)
Diagnosis and management of follicular lymphoma: A comprehensive review
Reyad Dada
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
Maximizing the effectiveness of oral therapies in lymphoid cancers: research gaps and unmet needs
Alix Y. L. Zackon et al.
LEUKEMIA & LYMPHOMA (2019)
Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia
Ian W. Flinn et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen
Nirav N. Shah et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines
Stephen J. Schuster et al.
BLOOD (2019)
Duvelisib, an oral dual PI3K-, inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study
Ian W. Flinn et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
The PI3K/AKT pathway in obesity and type 2 diabetes
Xingjun Huang et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2018)
Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date
Felix A. Mensah et al.
ONCOTARGETS AND THERAPY (2018)
Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Steven E. Coutre et al.
HEMASPHERE (2018)
A Phase Ib Study of Alpelisib (BYL719), a PI3K alpha-Specific Inhibitor, with Letrozole in ER+/HER2(-) Metastatic Breast Cancer
Ingrid A. Mayer et al.
CLINICAL CANCER RESEARCH (2017)
The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer
Kai Wang et al.
HUMAN PATHOLOGY (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
Dejan Juric et al.
CANCER DISCOVERY (2017)
A first-in-human phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: Results of dose-escalation phase.
A. Patnaik et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era
Moaath Mustafa Ali et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
M. Dreyling et al.
ANNALS OF ONCOLOGY (2017)
Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL
Tabea Erdmann et al.
BLOOD (2017)
Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT
Juliane Paul et al.
CANCER CELL (2017)
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
A. Patnaik et al.
ANNALS OF ONCOLOGY (2016)
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy
Vindi Jurinovic et al.
BLOOD (2016)
Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management
Khurum H. Khan et al.
ONCOLOGIST (2016)
Idelalisib-associated Colitis Histologic Findings in 14 Patients
Anna-Sophie Weidner et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2015)
First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
Geoffrey I. Shapiro et al.
CLINICAL CANCER RESEARCH (2015)
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
Carla Casulo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Management of adverse events associated with idelalisib treatment: expert panel opinion
Steven E. Coutre et al.
LEUKEMIA & LYMPHOMA (2015)
Constitutive AKT activation in follicular lymphoma
Ouardia I. Yahiaoui et al.
BMC CANCER (2014)
Impact of the healthcare payment system on patient access to oral anticancer drugs: an illustration from the French and United States contexts
Laure Benjamin et al.
BMC HEALTH SERVICES RESEARCH (2014)
Tumour-infiltrating CD4+ and CD8+ lymphocytes as predictors of clinical outcome in glioma
S. Han et al.
BRITISH JOURNAL OF CANCER (2014)
Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab
Zi-Zhen Xu et al.
ANNALS OF HEMATOLOGY (2013)
BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
Ningshu Liu et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Management of indolent lymphoma: Where are we now and where are we going
Matthew A. Lunning et al.
BLOOD REVIEWS (2012)
Abstract 4478: BAY 80-6946, a highly potent and efficacious class I PI3K inhibitor, induces complete tumor regression or tumor stasis in rat xenograft tumor models with PIK3CA mutant or PTEN deletion
Ningshu Liu et al.
CANCER RESEARCH (2011)
Insulin says NO to cardiovascular disease
Qiujun Yu et al.
CARDIOVASCULAR RESEARCH (2011)
Regulation of arterial blood pressure by Akt1-dependent vascular relaxation
Jung Min Ha et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2011)
Targeting the PI3K/AKT/mTOR Pathway in Non-Hodgkin's Lymphoma: Results, Biology, and Development Strategies
Jonathan H. Schatz
CURRENT ONCOLOGY REPORTS (2011)
Specific Roles of the p110α Isoform of Phosphatidylinsositol 3-Kinase in Hepatic Insulin Signaling and Metabolic Regulation
Victoria Rotter Sopasakis et al.
CELL METABOLISM (2010)
Mechanisms of Disease: Aggressive Lymphomas.
Georg Lenz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Contribution of Insulin and Akt1 Signaling to Endothelial Nitric Oxide Synthase in the Regulation of Endothelial Function and Blood Pressure
J. David Symons et al.
CIRCULATION RESEARCH (2009)
Targeting the phosphoinositide 3-kinase pathway in cancer
Pixu Liu et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Stromal Gene Signatures in Large-B-Cell Lymphomas
G. Lenz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Lack of endothelial nitric oxide synthase promotes endothelin-induced hypertension: Lessons from endothelin-1 transgenic/endothelial nitric oxide synthase knockout mice
Thomas Quaschning et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling
Zachary A. Knight et al.
CELL (2006)
A pharmacological map of the PI3-K family defines a role for p110 alpha in insulin signaling
Zachary A. Knight et al.
CELL (2006)
Exploiting the PI3K/AKT pathway for cancer drug discovery
BT Hennessy et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Mechanisms regulating phosphoinositide 3-kinase signalling in insulin-sensitive tissues
PR Shepherd
ACTA PHYSIOLOGICA SCANDINAVICA (2005)
Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser1179
M Montagnani et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
分享论文
